Ypsomed Holding stock
Price history
+30.52% over the period1 year: from CHF 327.00 (November 17, 2025) to CHF 426.80 (November 17, 2026), +30.52%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | CHF 426.80 |
| October 30, 2026 | CHF 394.80 |
| September 30, 2026 | CHF 366.00 |
| August 31, 2026 | CHF 397.80 |
| July 31, 2026 | CHF 385.20 |
| June 30, 2026 | CHF 364.80 |
| May 29, 2026 | CHF 350.40 |
| April 30, 2026 | CHF 273.00 |
| March 31, 2026 | CHF 276.00 |
| February 27, 2026 | CHF 267.00 |
| January 30, 2026 | CHF 305.50 |
| December 30, 2025 | CHF 328.00 |
| November 28, 2025 | CHF 330.50 |
| November 17, 2025 | CHF 327.00 |
At a glance
The company
Develops, manufactures and sells injection and infusion systems for self-medication across hospitals, doctors, pharmacies and patients
Latest results
Quarter to March 31, 2026 · EPS CHF 6.10 (estimate CHF 6.92)
TickerLandia's take on Ypsomed Holding
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 26 vs a median of 52 over its last 9 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 34 vs 34 (−0%) in a group of 10.
- Strong point: Profitability (81/100 in its group). Weak point: Earnings stability (37/100).
- “Below historical valuation” (Switzerland): No. 1 of 5.
- “Beat the market” (Switzerland): No. 6 of 83.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−3.61% from the 52-week high
Analysts · 14 analysts
Average targetCHF 413.71−1.92% vs. price
Buy 8 · Hold 4 · Sell 2 · Buy
TickerLandia Fingerprint: Ypsomed Holding
Compared with similar companies: very high profitability.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh65
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 34.3 45 Price/book 7.59 78 Price/sales 7.77 78 Forward P/E 29.0 66 EV/EBITDA 18.1 60 Profitabilityvery high81
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 36.2% 99 Gross margin 43.0% 31 Net margin 30.4% 99 ROE 31.1% 96 ROA 12.4% 84 Earnings stabilitylow37
How steady its margins were over the last five annual reports.
Metric Value Position in group Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Margin variabilitycounts in reverse: lower means more earnings stability 11.8% 10 Growthaverage51
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +13.69% 90 Revenue growth (year over year) −13.30% 2 Earnings growth (year over year) +51.70% 62 Financial strengthaverage57
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 83.2 92 Debt/equitycounts in reverse: lower means more financial strength 0.35 53 Current ratio 1.07 21 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.26 61 Dividendaverage42
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 19 years 44 Dividend yield 1.0% 37 Payout ratio 34.9% 44 Market momentumstrong77
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −1.02% 49 Relative strength (6 months) +25.18% 91 1-year return +28.99% 74 Distance from 200-day average +22.69% 94 Riskaverage51
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 23.6% 48 Volatility (60 days) 30.3% 61 Beta (1 year) 0.68 44
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Ypsomed Holding is cheaper than in the past and in line with similar companies
On the latest fiscal year's earnings (2026), Ypsomed Holding's P/E today is 26.2, below the median of its last 9 fiscal years (51.8; between 16.9 and 133.8 from 2017 to 2026). Ypsomed Holding's P/E (trailing 12 months): 34.3, in line with the median of a group of 10 similar companies (34.3).
Compared with 10 similar companies
| Metric | Ypsomed Holding | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 34.3 | Middle | |
| Forward P/E | 29.0 | Middle | |
| Operating margin | 36.2% | High | |
| ROE | 31.1% | High | |
| Debt/equity | 0.35 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Ypsomed Holding. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
CHF 368.29M
Latest quarter · Q1 2026
Net income
CHF 82.83M
Latest quarter · Q1 2026
Quarterly net margin
22.5%
Latest quarter · Q1 2026
Numbers and valuation
Full valuation- Market cap
- CHF 5.68B
- P/E
- 34.3
- EPS
- CHF 12.61
- Volume
- 3.02K
- Daily trading
- €7.45M
- Dividend yield
- 1.04%
- Last ex-dividend on July 3, 2026
How Ypsomed Holding is changing
All resultsRevenue grew 12.6% a year on average over the last 5 years
Operating margin rose from 8.7% to 36.2%
Less cash than profit: free cash flow equal to 0% of net income
Returns
Ypsomed Holding returns with dividends
CHF 1,000 invested in Ypsomed Holding 5 years ago, on November 17, 2021, would be worth CHF 2,393 today with dividends reinvested: +139.30% in total, +19.07% per year. On price alone it would be CHF 2,307 (+130.66%).
| Period | Ypsomed Holding | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | +13.39% | +4.53% | CHF 1,134 |
| 6 months | +42.21% | +13.61% | CHF 1,422 |
| Year to date | +30.12% | +13.20% | CHF 1,301 |
| 1 year | +32.12% | +19.22% | CHF 1,321 |
| 3 years | +59.29% | +39.88% | CHF 1,593 |
| 5 years | +139.30% | +19.20% | CHF 2,393 |
| 10 years | +153.25% | +88.57% | CHF 2,533 |
Over the last 6 months it has done better than 64% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment
The chart in detail
Ypsomed Holding: technical analysis
Ypsomed Holding is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 3.5% below its all-time closing high (CHF 437.20, November 12, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 65
- Between 30 and 70
- vs 200-session average
- +22.69%
Support and resistance
Price areas where Ypsomed Holding has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last priceCHF 421.80
- SupportCHF 417.00−1.14%3 touches, last on September 3, 2026
- SupportCHF 371.27−11.98%3 touches, last on September 24, 2026
- SupportCHF 355.12−15.81%6 touches, last on October 8, 2026
Volatility and risk
Over the last year it has moved less than the SMI.
- Beta (1 year) vs SMI
- 0.68
- Volatility (60 sessions, annualised)
- 30.3%
- Largest fall in the last year
- −23.61%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Ypsomed Holding: seasonality
Average monthly price change over 23 years
Over the last 23 years, the strongest month for Ypsomed Holding has been November: +4.78% on average, positive in 14 years out of 22. The weakest has been September: −3.03% on average, positive in 8 years out of 22.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.52% | +1.08% | 12 of 22 |
| February | −0.42% | −1.66% | 9 of 22 |
| March | +0.86% | +0.57% | 13 of 22 |
| April | +0.06% | +0.05% | 11 of 22 |
| May | +4.02% | +4.18% | 13 of 22 |
| June | +0.05% | −0.80% | 10 of 22 |
| July | −1.68% | −0.35% | 8 of 22 |
| August | +1.86% | +1.56% | 13 of 22 |
| September | −3.03% | −0.90% | 8 of 22 |
| October | +2.01% | +1.45% | 13 of 23 |
| November | +4.78% | +1.24% | 14 of 22 |
| December | +0.65% | −0.51% | 9 of 22 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Ypsomed Holding and its competitors
Sales reach Switzerland, Europe, North America and other markets worldwide, where the group develops, manufactures and sells systems that allow patients to administer medication themselves. Its range covers pen injectors, auto-injectors and wearable injectors, together with related services, and it also makes infusion sets and reservoirs under contract. Products are marketed to hospitals, doctors, pharmacies and patients through subsidiaries and distributors.
- Headquarters
- Burgdorf, Switzerland
- Employees
- 2,025
- Founded
- 1984
- Chief executive
- Simon Michel
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Ypsomed HoldingYPSN | $6.76B | 36.2% | 34.3 | +42.21% |
| ConvaTec GroupCTEC | $6.51B | 16.3% | 51.6 | +18.65% |
| Fielmann GroupFIE | $4.05B | 13.7% | 16.9 | +1.29% |
| SCHOTT Pharma1SXP | $3.69B | 16.4% | 24.8 | +37.06% |
| Tecan GroupTECN | $3.65B | 4.9% | — | +72.98% |
| Carl Zeiss MeditecAFX | $3.37B | 7.2% | 25.2 | +38.26% |
Same industry or related industries, similar size. Compare Ypsomed Holding with its competitors · Full profile
